Drug class
Recombinant human coagulation factor XIII A-subunit (rFXIII-A2); haemostatic biologic
Mechanism of action
Replaces the deficient factor XIII A-subunit. Factor XIII is activated by thrombin and calcium and cross-links fibrin, stabilising the fibrin clot and supporting resistance to fibrinolysis.
General use cases
- Long-term prophylaxis of bleeding in adults and paediatric patients aged 6 years and older with congenital factor XIII A-subunit deficiency
- Treatment of breakthrough bleeding episodes and selected perioperative bleeding prevention in patients receiving prophylaxis, according to product-specific instructions
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
